Authors : Kella Devika; Dr. N. Phani Satyavathi; Ch. Bhargavi; E. Varshitha

Volume/Issue : Volume 10 - 2025, Issue 3 - March

Google Scholar : https://tinyurl.com/3rzsy4t5

Scribd : https://tinyurl.com/wtccycjw

DOI : https://doi.org/10.38124/ijisrt/25mar996

Google Scholar

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 15 to 20 days to display the article.

Abstract : Parkinson's disease (PD) may be a dynamic neurological disorder brought on by dopaminergic neuron loss in the substantia nigra, a fundamental location of the brain effective for guiding development. The unfortunate fate of these neurons results in a deficiency in dopamine, a neurotransmitter vital for engine control, which produces symptoms including tremor, solidity, bradykinesia (graduality of development), and postural flimsiness, adjacent non-motor complications including cognitive decay and disposition clusters follow. Stem cell treatment addresses the basic causes of PD, thereby reflecting a transforming wilderness in care. This method suggests to replace the lost or damaged neurons, reestablish dopamine creation, and maybe stop or switch malady movement by using the one-of-a-kind regenerative capacity of stem cells. Actuated pluripotent stem cells (iPSCs), rebuilt from grown-up cells and advertising a patient- specific, moral elective; key stem cells investigated incorporate embryonic stem cells, which have tall pluripotency and can separate into dopaminergic neurons; mesenchymal stem cells, known for their neuroprotective and anti-inflammatory properties. This article examines the intricate factors via which stem cells interact with the damaged neuronal environment, facilitating healing and regeneration. It also covers important issues including moral questions, tumorigenicity, safe dismissal, and therapeutic adaptability. Moreover, it emphasizes developments in clinical trials, counting efforts to make strides cell conveyance techniques, increase cell survival, and guarantee useful integration into the brain's circuitry. By not as it was supervising signs but rather by addressing the root cause of neuronal misfortune, stem cell treatment eventually has the potential to transform Parkinson's disease treatment advertising trust for forward persistent outcomes and quality of life.

Keywords : Parkinson’s Disease, Dopamine, Stem Cells , Pathological Mechanism , Midbrain Dopaminergic Neurons, Future Perspectives In Parkinson’s Disease.

References :

1. D.J Anderson Stem cells and pattern formation in the nervous system The possible versus the actual Neuron (2001)
2. Lee VM, Trojanowski JQ. Mechanisms of Parkinson’s disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 2006;
3. Ola now CW, Tatton WG. Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci 1999
4. Parmar, M, Grealish, S, and Henchcliffe, C. The future of stem cell therapies for Parkinson disease. Nat Rev Neurosci. (2020) 21:103–15. Doi: 10.1038/s41583-019-0257-7
5.  Tansey, MG, Walling’s, RL, Houser, MC, Herrick, MK, Keating, CE, and Joers, V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. (2022) 22:657–73. Doi: 10.1038/s41577-022-00684-6
6. Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron 2003; 39:889-909
7. Lee VM, Trojanowski JQ. Mechanisms of Parkinson’s disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 2006; 52:33-38
8. Henderson MX, Trojanowski JQ, Lee VM. α-Synuclein pathology in Parkinson’s disease and related α-synucleinopathies. Neurosci Lett 2019;709:134316
9. Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. TransNeu-rodegener 2015; 4:19
10. Golpich M, Amini E, Mohamed Z, Azman Ali R, Mohamed Ibrahim N, Ahmadiani A. Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: pathogenesis and treatment. CNS Neurosci Ther 2017; 23:5-22
11. Chu YT, Tai CH, Lin CH, Wu RM. Updates on the genetics of Parkinson’s disease: clinical implications and future treatment. Acta Neurol Taiwan 2021; 30:83-93 
12. Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, et al. Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J Neurosci 2011; 31:14508-14520
13. Salehi M, Pasbakhsh P, Soleimani M, Abbasi M, Hasanzadeh G, Modaresi MH. et al. Repair of spinal cord injury by co-transplantation of embryonic stem cell-derived motor neuron and olfactory ensheathing cell. Iranian Biomedical Journal. 2009;13(3):125–35. [PubMed] [Google Scholar]
14. 36.Kim J-H, Auerbach JM, Rodríguez-Gómez JA, Velasco I, Gavin D, Lumelsky N. et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature. 2002;418(6893):50–6. Doi: 10.1038/nature00900. [DOI] [PubMed] [Google Scholar]
15.  Brederlau A, Correia AS, Anisimov SV, Elmi M, Paul G, Roybon L. et al. Transplantation of Human Embryonic Stem Cell‐Derived Cells to a Rat Model of Parkinson's Disease: Effect of In Vitro Differentiation on Graft Survival and Teratoma Formation. Stem Cells. 2006;24(6):1433–40. doi: 10.1634/stemcells.2005-0393. [DOI] [PubMed] [Google Scholar]
16. Erdo F, Bührle C, Blank J, Hoehn M, Xia Y, Fleischmann B. et al. Host-dependent tumorigenesis of embryonic stem cell transplantation in experimental stroke. Journal of Cerebral Blood Flow & Metabolism. 2003;23(7):780–5. Doi: 10.1097/01.WCB.0000071886. 63724.FB. [DOI] [PubMed] [Google Scholar]
17. Takagi Y, Takahashi J, Saiki H, Morizane A, Hayashi T, Kishi Y. et al. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. Journal of Clinical Investigation. 2005;115(1):102–9. Doi: 10.1172/JCI21137. [DOI] [PMC free article] [PubMed] [Google Scholar]
18. Nadri S, Soleimani M, Mobarra Z, Amini S. Expression of dopamine-associated genes on conjunctiva stromal-derived human mesenchymal stem cells. Biochemical and biophysical research communications. 2008;377(2):423–8. Doi: 10.1016/j.bbrc.2008.09.148. [DOI] [PubMed] [Google Scholar]
19. 1 Pittenger M. F., Mackay A. M., Beck S. C., Jaiswal R. K., Douglas R., Mosca J. D., Moorman M. A., Simonetti D. W., Craig S., and Marshak D. R., Multilineage potential of adult human mesenchymal stem cells, Science. (1999) 284, no. 5411, 143–147, 2-s2.0-0033515827, https://doi.org/10.1126/science.284.5411.143.
20.  Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I. et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Archives of neurology. 2010;67(10):1187. Doi: 10.1001/archneurol.2010.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
21. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proceedings of the National Academy of Sciences. 1999;96(19):10711–6. Doi: 10.1073/pnas.96.19.10711. [DOI] [PMC free article] [PubMed] [Google Scholar]
22. Kitada M, Dezawa M. Parkinson's disease and mesenchymal stem cells: potential for cell-based therapy. Parkinson's disease. 2012;2012 Doi: 10.1155/2012/873706. [DOI] [PMC free article] [PubMed] [Google Scholar]
23. Laurent LC, Ulitsky I, Slavin I, Tran H, Schork A, Morey R. et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell stem cell. 2011;8(1):106–18. Doi: 10.1016/j.stem.2010.12.003. [DOI] [PMC free
24. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. cell. 2007;131(5):861–72. Doi: 10.1016/j.cell.2007.11.019. [DOI] [PubMed] [Google Scholar]
25. 68.Su P, Loane C, Politis M. The Use of Stem Cells in the Treatment of Parkinsons Disease. In sciences J. 2011;1(3):136–56. [Google Scholar]
26. Kitada M, Dezawa M. Parkinson's disease and mesenchymal stem cells: potential for cell-based therapy. Parkinson's disease. 2012;2012 Doi: 10.1155/2012/873706. [DOI] [PMC free article] [PubMed] [Google Scholar]
27. Wernig M, Zhao J-P, Pruszak J, Hedlund E, Fu D, Soldner F. et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proceedings of the National Academy of Sciences. 2008;105(15):5856–61. Doi: 10.1073/pnas.0801677105. [DOI] [PMC free article] [PubMed] [Google Scholar]
28. Wernig M, Zhao J-P, Pruszak J, Hedlund E, Fu D, Soldner F. et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proceedings of the National Academy of Sciences. 2008;105(15):5856–61. Doi: 10.1073/pnas.0801677105. [DOI] [PMC free article] [PubMed] [Google Scholar]
29. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nature Reviews Cancer. 2011;11(4):268–77. Doi: 10.1038/nrc3034. [DOI] [PubMed] [Google Scholar]
30. Moriguchi H, Chung RT, Sato C. Tumorigenicity of human induced pluripotent stem cells depends on the balance of gene expression between p21 and p53. Hepatology. 2010;51(3):1088–9. Doi: 10.1002/hep.23396. [DOI] [PubMed] [Google Scholar]
31. Francis NL, Zhao N, Calvelli HR, Saini A, Giford JJ, Wagner GC, Cohen RI, Pang ZP, Moghe PV. Peptide-based scafolds for the culture and transplantation of human dopaminergic neurons. Tissue Eng Part A. 2020;26(3–4):193–205.
32. Cardoso T, Adler AF, Mattsson B, Hoban DB, Nolbrant S, Wahlestedt JN, A, Grealish S, Björklund A, Parmar M. Target-specific forebrain projections and appropriate synaptic inputs of he SC-derived dopamine neurons grafted to the midbrain of Parkinsonian rats. J Comp Neurol. 2018;526(13):2133–46
33. Wakeman DR, Hiller BM, Marmion DJ, McMahon CW, Corbett GT, Mangan KP, Ma J, Little LE, Xie Z, Perez-Rosello T, Guzman JN. Cryopreservation maintains functionality of human iPSC dopamine neurons and rescues Parkinsonian phenotypes in vivo. Stem Cell Rep. 2017;9(1):149–61.
34.  Petrus-Reurer S, Kumar P, Padrell Sánchez S, Aronsson M, André H, Bartuma H, Plaza Reyes A, Nandrot EF, Kvanta A, Lanner F. Preclinical safety studies of human embryonic stem cell-derived retinal pigment epithelial cells for the treatment of age-related macular degeneration. Stem Cells Trans Med. 2020;9(8):936–5
35. Shokravi S, Borisov V, Zaman BA, Niazvand F, Hazrati R, Khah MM, Thangavelu L, Marzban S, Sohrabi A, Zamani A. Mesenchymal stromal cells (MSCs) and their exosome in acute liver failure (ALF): a comprehensive review. Stem Cell Res Ther. 2022;13(1):192.
36. Kordower JH, Vinuela A, Chu Y, Isacson O, Redmond DE Jr. Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. J Comp Neurol. 2017;525(3):498–512.
37. Kordower JH, Vinuela A, Chu Y, Isacson O, Redmond DE Jr. Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. J Comp Neurol. 2017;525(3):498–512.
38.  Gugliandolo A, Bramanti P, Mazzon E. Mesenchymal stem cells in multiple sclerosis: recent evidence from pre-clinical to clinical studies. Int J Mol Sci. 2020;21(22):8662
39. Gugliandolo A, Bramanti P, Mazzon E. Mesenchymal stem cells in multiple sclerosis: recent evidence from pre-clinical to clinical studies. Int J Mol Sci. 2020;21(22):8662.
40.  Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Sclera J. 2018;24(4):501–11.
41. Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Sclera J. 2018;24(4):501–11.
42. Horak J, Nalos L, Martinkova V, Tegl V, Vistejnova L, Kuncova J, Kohoutova M, Jarkovska D, Dolejsova M, Benes J, Stengl M. Evaluation of mesenchymal stem cell therapy for sepsis: a randomized controlled porcine study. Front Immunol. 2020;7(11):126.
43. Yang G, Van Kaer L. Therapeutic targeting of immune cell autophagy in multiple sclerosis: Russian roulette or silver bullet? Front Immunol. 2021;31(12): 724108.
44.  Yuan TF, Dong Y, Zhang L, Qi J, Yao C, Wang Y, Chai R, Liu Y, So KF. Neuromodulation-based stem cell therapy in brain repair: recent advances and future perspectives. Neurosci Bull. 2021; 37:735
45. Bose G, Thebault S, Rush CA, Atkins HL, Freedman MS. Autologous hematopoietic stem cell transplantation for multiple sclerosis: a current perspective. Mult Sclera J. 2021;27(2):167–73.
46.  Barati S, Tahmasebi F, Faghihi F. Effects of mesenchymal stem cells transplantation on multiple sclerosis patients. Neuropeptides. 2020;1(84): 102095.
47. Barati S, Tahmasebi F, Faghihi F. Effects of mesenchymal stem cells transplantation on multiple sclerosis patients. Neuropeptides. 2020;[84]:102095
48.  Tupone MG, D’Angelo M, Castelli V, Catanesi M, Benedetti E, Cimini. A state-of-the-art of functional scafolds for 3D nervous tissue regeneration. Front Bioeng Biotechnol. 2021;18(9): 639765.
49. Konovalova J, Gerasymchuk D, Parkkinen I, Chmielarz P, Domanskyi A. Interplay between MicroRNAs and oxidative stress in neurodegenerative diseases. Int J Mol Sci. 2019;20(23):6055.
50.  Farina M, Vieira LE, Buttari B, Profumo E, Saso L. The Nrf2 pathway in ischemic stroke: a review. Molecules. 2021;26(16):5001.
51. Wu L, Lu J, Lan T, Zhang D, Xu H, Kang Z, Peng F, Wang J. Stem cell therapies: a new era in the treatment of multiple sclerosis. Front Neurol. 2024;9(15):1389697. 53